SAR405: Selective ATP-Competitive Vps34 Inhibitor for Autophagy and Lysosome Research

Executive Summary: SAR405 is a potent and highly selective ATP-competitive inhibitor of Vps34 (class III PI3K), with a K_d of 1.5 nM and IC₅₀ of 1 nM against human recombinant Vps34, showing no inhibition of class I/II PI3Ks or mTOR at concentrations up to 10 μM (APExBIO). Its inhibition of Vps34 impairs autophagosome formation, disrupts late endosome-lysosome function, and blocks cathepsin D maturation (Park et al., 2023). SAR405 is crucial for mechanistic studies in cancer research and neurodegenerative disease models due to its exquisite selectivity and compatibility with standard cell lines. It synergizes with mTOR inhibitors such as everolimus, enabling advanced pathway dissection. Storage and solubility parameters are established, making SAR405 a robust, reproducible tool for autophagy research (APExBIO).

Biological Rationale

Autophagy is a conserved eukaryotic process responsible for degrading and recycling cytoplasmic components to maintain cellular homeostasis, especially under nutrient deprivation (Park et al., 2023). The class III phosphoinositide 3-kinase Vps34 is central to autophagosome initiation and vesicle trafficking (APExBIO). Dysregulation of autophagy and lysosomal pathways contributes to cancer progression, neurodegeneration, and metabolic diseases. Inhibitors targeting Vps34 allow researchers to dissect these pathways with precision, distinguishing the roles of autophagy in survival versus cell death, particularly under energy or nutrient stress conditions. Recent work has redefined the AMPK-ULK1-Vps34 axis, showing that AMPK activation can suppress rather than induce autophagy under energy deprivation, challenging previous models (Park et al., 2023).

Mechanism of Action of SAR405

SAR405 (A8883, APExBIO) is an ATP-competitive inhibitor that binds selectively to the ATP-binding cleft of Vps34. This binding blocks the kinase activity required for the production of phosphatidylinositol 3-phosphate (PI3P), a lipid crucial for autophagosome nucleation (Vatalis). SAR405 exhibits a K_d of 1.5 nM and an IC₅₀ of 1 nM in human recombinant Vps34 enzyme assays. Notably, it displays no detectable inhibition of class I and II PI3Ks or mTOR at concentrations up to 10 μM, underscoring its selectivity (APExBIO). Inhibition of Vps34 by SAR405 impairs late endosome-lysosome maturation, causes the accumulation of enlarged late endosomes/lysosomes, and blocks the conversion of pro-cathepsin D to its mature form. In cell models, such as GFP-LC3 HeLa and H1299 cells, SAR405 prevents autophagosome formation and suppresses autophagy (Rapamycin US). Furthermore, SAR405 can be combined with mTOR inhibitors (e.g., everolimus) to achieve synergistic autophagy inhibition.

Evidence & Benchmarks

• SAR405 exhibits a dissociation constant (K_d) of 1.5 nM and an IC₅₀ of 1 nM against human recombinant Vps34 in vitro (APExBIO).
• No inhibition of class I and II PI3Ks or mTOR is observed at concentrations up to 10 μM, confirming exceptional selectivity (APExBIO).
• In HeLa and H1299 cells expressing GFP-LC3, SAR405 prevents autophagosome formation, indicating functional autophagy inhibition (Park et al., 2023).
• SAR405 impairs late endosome-lysosome function, causing swollen vesicular compartments and defective cathepsin D maturation (APExBIO).
• Synergistic inhibition of autophagy is achieved when SAR405 is combined with mTOR inhibitors such as everolimus (Rapamycin US).
• SAR405 is soluble in DMSO (>10 mM), insoluble in water, and can be dissolved in ethanol using ultrasonic assistance (APExBIO).
• Recommended storage is as a stock solution below -20°C; long-term storage of solutions is discouraged due to stability concerns (APExBIO).
• Recent studies clarify that Vps34 inhibition by SAR405 allows researchers to decouple canonical autophagy regulation from energy-sensing pathways involving AMPK and mTOR (Park et al., 2023).

This article extends prior summaries such as Vatalis and Rapamycin US by integrating recent mechanistic updates and benchmarking SAR405's selectivity in light of new AMPK-ULK1-Vps34 pathway findings. For troubleshooting and workflow integration, see the detailed guide at Tamra Azide; this article focuses on validated selectivity and reproducibility benchmarks.

Applications, Limits & Misconceptions

SAR405 is widely used in preclinical research to study autophagy inhibition, vesicle trafficking modulation, and lysosome function impairment. Its nanomolar potency and selectivity make it suitable for dissecting Vps34 kinase signaling in cancer cells, neurons, and other disease-relevant models (APExBIO). Applications include:

• Dissecting autophagosome formation blockade in live-cell imaging assays.
• Studying the impact of autophagy inhibition on cell survival in cancer and neurodegenerative models.
• Combining with mTOR inhibitors to parse out distinct regulatory mechanisms.
• Mapping vesicle trafficking defects and lysosomal maturation.

However, limitations and misconceptions exist:

Common Pitfalls or Misconceptions

• SAR405 does not inhibit class I/II PI3Ks or mTOR at concentrations ≤10 μM; off-target effects in these pathways should be considered highly unlikely (APExBIO).
• It is ineffective in water-based solutions due to insolubility; DMSO or ethanol (with sonication) are required for stock preparation.
• SAR405 is not suitable for in vivo applications unless formulation and pharmacokinetic data are explicitly established.
• Prolonged storage of SAR405 solutions (>2–3 weeks) may lead to compound degradation; always prepare fresh aliquots for reproducibility.
• Autophagy inhibition by SAR405 should not be interpreted as a direct effect on AMPK or ULK1 signaling; it acts strictly at the level of Vps34 (Park et al., 2023).

Workflow Integration & Parameters

For optimal experimental results, SAR405 should be dissolved in DMSO at concentrations >10 mM. If ethanol is used, ultrasonic assistance is recommended to enhance solubility. Working dilutions should be prepared freshly prior to use, and stock solutions stored at -20°C. In cellular assays, SAR405 is typically used at nanomolar to low micromolar concentrations, tailored to the cell type and endpoint (APExBIO). Standard readouts include GFP-LC3 puncta quantification, endosomal morphology by fluorescence or electron microscopy, and cathepsin D maturation via immunoblot. For pathway dissection, SAR405 can be combined with mTOR inhibitors such as everolimus to achieve synergistic autophagy inhibition (Rapamycin US). Researchers should validate lack of cytotoxicity and confirm selectivity using control inhibitors.

Conclusion & Outlook

SAR405, offered by APExBIO, is a reference-standard tool for selective inhibition of Vps34-mediated autophagy and vesicle trafficking. Its exceptional selectivity, reproducibility, and well-characterized mechanism make it indispensable for probing the molecular basis of autophagy in cancer, neurodegenerative, and metabolic disease models. Recent updates in autophagy signaling underscore the value of SAR405 for pathway-specific dissection, especially in combination with energy-sensing modulators. Ongoing research will clarify SAR405's role in translational applications and in vivo models, contingent on formulation advances and PK/PD profiling.